DV
Dividend Vision

ELTX — Elicio Therapeutics Inc.

Elicio Therapeutics Inc. (ELTX)

Total return is -98.2% over the past 5.5 years, 213.9 points behind SPY at 115.7%. Its deepest 1-year drawdown was 81.4%.

This is a single-stock equity holding in Elicio Therapeutics Inc., a biotechnology company, rather than a diversified ETF. The stock does not currently pay dividends, making it unsuitable for income-focused investors seeking regular distributions. It appeals primarily to growth-oriented investors interested in exposure to the therapeutic development sector, though it carries the concentration risk inherent to single-stock investments.

ELTX key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2021
Distribution frequency
None
Last close
$3.09
Market cap
$81,211,016
Average volume
154600.0
Beta
1.877
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.30